A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Fentanyl Vaccine in Patients with Opioid-Induced Respiratory Depression

The primary objective of this phase 1 study is to evaluate the safety and tolerability of a fentanyl vaccine. This investigation is clinically relevant to mitigate the risks associated with opioid-induced respiratory depression. No secondary objectives were specified.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers. The cohort includes both male and female individuals. The participants fall within the age range designated by code 3. The clinical focus involves the management or assessment of opioid induced respiratory depression.

This Phase 1 study evaluates a fentanyl vaccine for the prevention of opioid-induced respiratory depression. The research methodology involves a structured sequence of study visits starting with a screening visit to assess eligibility. Following enrollment, participants undergo scheduled follow-up visits to monitor safety and physiological responses, concluding with an end-of-study visit. The total duration of participant involvement is determined by the clinical protocol. Early termination from the study may occur based on predefined safety criteria or clinical conditions.

Efficacy assessment in this clinical trial pertains to the management of opioid-induced respiratory depression. The parameters utilized to evaluate the therapeutic effect include specific endpoints related to the condition.